Webinar

Empowering laboratories with robust molecular analysis: Unlocking MSK-ACCESS®

On-demand

SOPHiA GENETICS has launched MSK-ACCESS® powered with SOPHiA DDM™!

This decentralized version of the highly validated liquid biopsy assay developed and routinely used by Memorial Sloan Kettering Cancer Center (MSK) uses a matched tumor-normal approach to reduce noise and the risk of biological false positives. By combining MSK’s clinical expertise in cancer genomics and the robust algorithms of the SOPHiA DDM™ Platform, we can support laboratories worldwide with their precision cancer analysis capabilities.

Learning Objectives:

  • Understand the advantages of using a matched tumor-normal approach to reduce noise and the risk of biological false positives.  
  • Learn about the clinical implementation and benefits of MSK-ACCESS® at MSK and its evolution from version 1 to the expanded version 2.  
  • Explore the analytical concordance data of MSK-ACCESS® powered with SOPHiA DDM™ for liquid biopsy. 

Brian Loomis, PhD

Director of Clinical Next-Generation Sequencing, Department of Pathology and Laboratory Medicine, MSK, Memorial Sloan Kettering Cancer Center

Florian Klemm, MD, PhD

Technical Product Manager, Genomic Research Expert , SOPHiA GENETICS

Verena Schramm

VP, Product Management, SOPHiA GENETICS